The Department of Health in Abu Dhabi granted clearance for the testing of NEO212, an oral conjugate designed to treat aggressive brain tumors. This international expansion arrives after the company finalized its Phase 1 dose escalation, identifying 610 mg as the optimal dosage for the upcoming study.

Despite the regulatory nod, the path to patient enrollment remains subject to further administrative hurdles. NeOnc must secure approval from an institutional review board and finalize updates to its study protocol, investigator brochures, and product labeling. The company emphasized that this authorization is strictly limited to clinical research and does not constitute marketing approval.